EP1799685B1 - Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one - Google Patents

Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one Download PDF

Info

Publication number
EP1799685B1
EP1799685B1 EP05799991A EP05799991A EP1799685B1 EP 1799685 B1 EP1799685 B1 EP 1799685B1 EP 05799991 A EP05799991 A EP 05799991A EP 05799991 A EP05799991 A EP 05799991A EP 1799685 B1 EP1799685 B1 EP 1799685B1
Authority
EP
European Patent Office
Prior art keywords
compound
fluoro
methyl
tetrahydro
azepino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05799991A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1799685A2 (en
Inventor
Jia Agouron Pharmaceuticals Inc. LIU
Naresh Agouron Pharmaceuticals Inc. NAYYAR
Ming Agouron Pharmaceuticals Inc. A Pfizer Company GUO
Zhen-Ping Agouron Pharmaceuticals Inc. WU
Agouron Pharmaceuticals Inc. BORER Bennett C.
A.N. Agouron Pharmaceuticals Inc. SRIRANGAM
Mark B. Agouron Pharmaceuticals Inc. MITCHELL
Yi Agouron Pharmaceuticals Inc. LI
Jan-Jon Agouron Pharmaceuticals Inc. CHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Pfizer Inc
Original Assignee
Cancer Research Technology Ltd
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, Pfizer Inc filed Critical Cancer Research Technology Ltd
Publication of EP1799685A2 publication Critical patent/EP1799685A2/en
Application granted granted Critical
Publication of EP1799685B1 publication Critical patent/EP1799685B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel polymorphic forms of the phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to methods for their preparation.
  • the invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.
  • the compound 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one represented by formula 1 is a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP).
  • PARP poly(ADP-ribose) polymerase
  • the compound of formula 1 and salts thereof, can be prepared as described in U.S. Patent No. 6,495,541 ; PCT Application No. PCT/IB2004/000915, International Publication No. WO 2004/087713 ; and U.S. Provisional Patent Application No. 60/612,457 .
  • PARP-1 and PARP-2 are stimulated by DNA strand breaks
  • PARP-3 interacts with PARP-1 and the centrosome
  • PARP-4 also known as vault PARP (VPARP)
  • PARP-5a and 5b are associated with telomeric proteins
  • TiPARP poly(ADP-ribosylate) histones
  • Enzyme-mediated repair of single- or double-strand breaks in DNA is a potential mechanism of resistance to radiotherapy or cytotoxic drugs whose mechanism depends on DNA damage. Inhibition of DNA repair enzymes is thus a strategy for the potentiation of these agents.
  • PARP-1 the best-characterized member of the PARP family, is a nuclear enzyme that upon activation by DNA damage mediates the transfer of ADP-ribose fragments from NAD + to a number of acceptor proteins. Depending on the extent of DNA damage incurred, PARP-1 activation and subsequent poly(ADP-ribosyl)ation mediate the repair of the damaged DNA or induce cell death. When DNA damage is moderate, PARP-1 plays a significant role in the DNA repair process.
  • inhibitors of this enzyme may have a role as chemosensitizing agents (by preventing DNA repair, for example, after anticancer therapy), or as treatments for a variety of disease and toxic states that involve oxidative or nitric oxide induced stress and subsequent PARP hyperactivation.
  • Such conditions include neurologic and neurodegenerative disorders (e.g., Parkinson's disease, Alzheimer's disease) ( Love S, Barber R, Wilcock GK.
  • Diabetic endothelial dysfunction role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 2001;79:437-48 ); arthritis ( Szab6 C, Virág L, Cuzzocrea S, et al. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci USA 1998;95:3867-72 ); and cisplatin-induced nephrotoxicity ( Racz I, Tory K, Gallyas F, et al.
  • BGP-15 a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol 2002;63:1099-111 ). Furthermore, it was shown that BRCA2 deficient tumor cells are acutely sensitive to PARP-1 inhibitors alone ( Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T. "Specific killing of BRCA2 deficient tumors with inhibitors of poly(ADP-ribose)polymerase," Nature : in press).
  • PARP inhibitors are also involved in enhancing the induction of the expression of Reg gene in p cells and HGF gene and, accordingly, promote the proliferation of pancreatic ⁇ -cells of Langerhans' islets and suppress apoptosis of the cells ( U.S. Patent Application Publication 2004/0091453 ; PCT Publication No. WO 02/00665 ).
  • PARP inhibitors are also used in cosmetic preparations, especially in after-sun lotions ( PCT Publication No. WO 01/82877 ). There are no marketed PARP inhibitors presently.
  • 60/612,458 and 60/683,006 entitled “Therapeutic Combinations Comprising Poly(ADP-Ribose) Polymerases Inhibitor,” describe pharmaceutical combinations of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one.
  • the invention provides a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form I, having a X-ray powder diffraction pattern comprising peaks at diffraction angles (2 ⁇ ) of 10.9, 19.3, 22.9, and 25.0, and wherein said polymorph is a hydrate.
  • the invention provides a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form II, having a X-ray powder diffraction pattern comprising peaks at diffraction angles (2 ⁇ ) of 11.2, 14.0, 20.1, and 23.1, and wherein said polymorph is anhydrous.
  • the invention provides a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form III, having a X-ray powder diffraction pattern comprising peaks at diffraction angles (2 ⁇ ) of 10.7, 11.0, 19.4, and 25.1, and wherein said polymorph is a hydrate.
  • the invention provides a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form V, having an X-ray powder diffraction pattern comprising peaks at diffraction angles (2 ⁇ ) of 10.8, 14.8, 21.6, and 25.8, and wherein said polymorph is a hydrate.
  • the invention provides a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form VI, having an X-ray powder diffraction pattern comprising peaks at diffraction angles (2 ⁇ ) of 14.8, 20.0, 22.3, and 23.5.
  • the invention provides a solid form of a phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the solid form comprises at least two of the above polymorph Forms I, II, III, V, VI.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form I as defined above.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form II as defined above.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form III as defined above.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form V as defined above.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form VI as defined above.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a solid form of a phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the solid form comprises at least two of the following forms: polymorph Forms I, II, III, V, VI, as defined above.
  • Also disclosed is a method of treating a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoroof 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form I as defined above.
  • Also disclosed is a method of treating a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form II as defined above.
  • Also disclosed is a method of treating a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form III as defined above.
  • Also disclosed is a method of treating a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form V as defined above.
  • Also disclosed is a method of treating a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ ,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form VI as defined above.
  • Also disclosed is a method of treating a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a solid form of a phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the solid form comprises at least two of the following forms: polymorph Forms I, II, III, V, VI as defined above.
  • Also disclosed is a method of treating cancer in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form I as defined above.
  • Also disclosed is a method of treating cancer in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form II as defined above.
  • Also disclosed is a method of treating cancer in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form III as defined above.
  • Also disclosed is a method of treating cancer in .a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form V as defined above.
  • Also disclosed is a method of treating cancer in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a crystalline phosphate salt of 8-fluoro-2- ⁇ 4-[(methyiamino)methyl]phenyl ⁇ 1,3,4,5-teiahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the salt is a substantially pure polymorph of Form VI as defined above.
  • Also disclosed is a method of treating cancer in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a solid form of a phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, wherein the solid form comprises at least two of the following forms: polymorph Forms I, II, III, V, VI as defined above.
  • Compound I refers to the phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one.
  • the compound of formula 1 refers to 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, free base.
  • active agent refers to a polymorphic form of the phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ("Compound I"), or to a solid form that comprises two or more polymorphic forms or amorphous form of the phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one (Compound I).
  • ambient temperature refers to a temperature condition typically encountered in a laboratory setting. This includes the approximate temperature range of about 20 to about 30°C.
  • amorphous refers to a non-crystalline form of a compound.
  • aqueous base refers to any organic or inorganic base.
  • Aqueous bases include, by way of example only, metal bicarbonates, such as sodium bicarbonate, potassium carbonate, cesium carbonate, and the like.
  • aromatic solvent refers to an organic solvent possessing an aromatic moiety, including by way of example only, benzene, toluene, xylene isomers or mixtures thereof, and the like.
  • chemical stability refers to a type of stability in which a particular compound maintains its chemical integrity, and includes, but is not limited to, thermal stability, light stability, and moisture stability.
  • detectable amount refers to an amount or amount per unit volume that can be detected using conventional techniques, such as X-ray powder diffraction, differential scanning calorimetry, HPLC, Fourier Transform Infrared Spectroscopy (FT-IR), Raman spectroscopy, and the like.
  • exposing to humidity refers to the process of exposing a substance to water vapor in a humidor, humidity chamber, or any apparatus capable of controlling relative humidity.
  • the term may also describe the process of exposing a substance to ambient humidity as during storage.
  • cancer includes, but is not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CN)
  • inert solvent refers to any solvent or liquid component of a slurry that does not chemically react with other components in a solution or slurry.
  • inert solvents include, by way of example only aprotic solvents such as aromatic solvents, ethyl acetate, acetone, methyl tert-butylether, dioxane, terahydrofuran (THF), and the like.
  • Protic solvents include, by way of example only, methanol, ethanol, propanol isomers, butanol isomers and the like.
  • PARP poly(ADP-ribose) polymerase
  • PARP poly(ADP-ribose) polymerase
  • the present invention discloses methods of modulating or inhibiting PARP activity, for example in mammals, by administering polymorphic forms of the phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one (Compound I), or a solid form that comprises two or more polymorphic forms of Compound I.
  • the activity or efficacy of polymorphs of Compound I, or a solid form that comprises two or more polymorphic forms of Compound I may be measured as described, for example, in U.S. Patent No. 6,495,541 and U.S. Provisional Patent Application No. 60/612,458 .
  • minimum amount refers to the least amount of solvent required to completely dissolve a substance at a given temperature.
  • polymorph refers to different crystalline forms of the same compound and other solid state molecular forms including pseudo-polymorphs, such as hydrates (e.g., bound water present in the crystalline structure) and solvates (e.g., bound solvents other than water) of the same compound.
  • pseudo-polymorphs such as hydrates (e.g., bound water present in the crystalline structure) and solvates (e.g., bound solvents other than water) of the same compound.
  • pseudo-polymorphs such as hydrates (e.g., bound water present in the crystalline structure) and solvates (e.g., bound solvents other than water) of the same compound.
  • hydrates e.g., bound water present in the crystalline structure
  • solvates e.g., bound solvents other than water
  • X-ray powder diffraction can be used to identify different polymorphs, or a solid form that comprises more than one polymorph, in a reproducible and reliable way ( S. Byrn et al, Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations, Pharmaceutical research, Vol. 12, No. 7, p. 945-954, 1995 ; J. K. Haleblian and W. McCrone, Pharmacetical Applications of Polymorphism, Journal of Pharmaceutical Sciences, Vol. 58, No. 8, p. 911-929, 1969 ). Crystalline polymorphic forms are of interest to the pharmaceutical industry and especially to those involved in the development of suitable dosage forms. If the polymorphic form is not held constant during clinical or stability studies, the exact dosage form used or studied may not be comparable from one lot to another.
  • Certain polymorphic forms may exhibit enhanced thermodynamic stability or may be more readily manufactured in high purity in large quantities, and thus are more suitable for inclusion in pharmaceutical formulations. Certain polymorphs may display other advantageous physical properties such as lack of hygroscopic tendencies, improved solubility, and enhanced rates of dissolution due to different lattice energies.
  • peak intensities refers to relative signal intensities within a given X-ray diffraction pattern. Factors which can affect the relative peak intensities are sample thickness and preferred orientation (i.e., the crystalline particles are not distributed randomly).
  • peak positions refers to X-ray reflection positions as measured and observed in X-ray powder diffraction experiments. Peak positions are directly related to the dimensions of the unit cell. The peaks, identified by their respective peak positions, have been extracted from the diffraction patterns for the various polymorphic Forms I, II, III, IV, V, and VI of the phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one (Compound I).
  • PEG refers to poly(ethylene glycol). PEG is commercially available having different ranges of polymer chain lengths and thus viscosities. PEG 400 is soluble in alcohols, acetone, benzene, chloroform, acetic acid, CCl 4 , and water.
  • pharmaceutically acceptable, carrier, diluent, or vehicle refers to a material (or materials) that may be included with a particular pharmaceutical agent to form a pharmaceutical composition, and may be solid or liquid.
  • solid carriers are lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include tlme-delay or time-release material known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate and the like.
  • composition refers to a mixture of one or more of the compounds or polymorphs described herein, or physiologically/pharmaceutically acceptable salts or solvates thereof, with other chemical components, such as physiologically/pharmaceutically acceptable carriers and excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
  • the term "recrystallize” refers to the process of completely dissolving a solid in a first solvent with heating if necessary, and then inducing precipitation, usually by cooling the solution, or by adding a second solvent in which the solid is poorly soluble.
  • relative humidity refers to the ratio of the amount of water vapor in air at a given temperature to the maximum amount of water vapor that can be held at that temperature and pressure, expressed as a percentage.
  • relative intensity refers to an intensity value derived from a sample X-ray diffraction pattern.
  • the complete ordinate range scale for a diffraction pattern is assigned a value of 100.
  • a peak having intensity falling between about 50% to about 100% on this scale intensity is termed very strong (vs); a peak having intensity falling between about 50% to about 25% is termed strong (s). Additional weaker peaks are present in typical diffraction patterns and are also characteristic of a given polymorph.
  • slurry refers to a solid substance suspended in a liquid medium, typically water or an organic solvent.
  • separating from refers to a step in a synthesis in which the desired agent is isolated from other non-desired agents, including, but not limited to any of the following steps: filtering, washing with extra solvent or water, drying with heat and or under vacuum.
  • substantially pure with reference to particular polymorphic forms of the phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one (Compound I) means the polymorphic form includes less than 10%, preferably less than 5%, preferably less than 3%, preferably less than 1% by weight of impurities, including other polymorphic forms of Compound I. Such purity may be determined, for example, by X-ray powder diffraction.
  • an “effective amount” is intended to mean that amount of an agent that significantly inhibits proliferation and/or prevents de-differentiation of a eukaryotic cell, e.g., a mammalian, insect, plant or fungal cell, and is effective for the indicated utility, e.g., specific therapeutic treatment.
  • terapéuticaally effective amount refers to that amount of the compound or polymorph being administered which will relieve to some extent one or more of the symptoms of the disorder being treated.
  • a therapeutically effective amount refers to that amount which has at least one of the following effects:
  • 2 theta value refers to the peak position based on the experimental setup of the X-ray diffraction experiment and is a common abscissa unit in diffraction patterns.
  • the experimental setup requires that if a reflection is diffracted when the incoming beam forms an angle theta ( ⁇ ) with a certain lattice plane, the reflected beam is recorded at an angle 2 theta (2 ⁇ ).
  • treat refers to a method of alleviating or abrogating a hyperproliferative disorder and/or its attendant symptoms. With regard particularly to cancer, these terms simply mean that the life expectancy of an individual affected with a cancer will be increased or that one or more of the symptoms of the disease will be reduced.
  • under vacuum refers to typical pressures obtainable by a laboratory oil or oil-free diaphragm vacuum pump.
  • X-ray powder diffraction pattern refers to the experimentally observed diffractogram or parameters derived therefrom. X-Ray powder diffraction patterns are characterized by peak position (abscissa) and peak intensities (ordinate).
  • the phosphate salt of 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one can exist in more than one polymorphic crystalline form.
  • These forms may be used in a formulated product for the treatment of a mammalian disease condition mediated by poly(ADP-ribose) polymerase (PARP) activity, including cancer.
  • PARP poly(ADP-ribose) polymerase
  • Each form may have one or more advantages over the others in bioavailability, stability, or manufacturability. Crystalline polymorphic forms of Compound I have been discovered which are likely to be more suitable for bulk preparation and handling than other polymorphic forms.
  • An amorphous form of Compound I also exists. Processes for producing these polymorphic forms and amorphous form in high purity are described herein. Also provided are processes for the preparation of each polymorphic and amorphous form of Compound I, substantially free from other polymorphic forms of Compound I. Additionally, the invention provides pharmaceutical formulations comprising Compound I in different polymorphic forms as discussed above, and discloses methods of treating a mammalian disease condition mediated by poly(ADP-ribose) polymerase (PARP) activity by administering such pharmaceutical formulations.
  • PARP poly(ADP-ribose) polymerase
  • the present invention provides several polymorph crystalline forms of Compound I.
  • Each crystalline form of Compound I can be characterized by one or more of the following: X-ray powder diffraction pattern (i.e., X-ray diffraction peaks at various diffraction angles (2 ⁇ )); melting point onset (and onset of dehydration for hydrated forms) as illustrated by endotherms of a Differential Scanning Calorimetry (DSC) thermogram; FT-IR spectral diagram pattern; Raman spectral diagram pattern; aqueous solubility; light stability under International Conference on Harmonization (ICH) high intensity light conditions; and physical and chemical storage stability.
  • DSC Differential Scanning Calorimetry
  • samples of polymorphic Forms I, II, III, IV (reference compound), V, and VI of Compound I were each characterized by the positions and relative intensities of peaks in their X-ray powder diffraction patterns.
  • the X-ray powder diffraction parameters differ for each of the polymorphic Forms I, II, III, IV, V, and VI of Compound I.
  • the X-ray powder diffraction pattern for each polymorph form of the invention was measured on a Shimadzu XRD-6000 or Bruker Discover D8 X-ray diffractometer equipped with a Cu X-ray source operated at 40 kV and 30 mA or 40 kV and 40 mA, respectively.
  • Shimadzu XRD-6000 X-ray diffractometer the samples were placed in a sample holder and then packed and smoothed with a glass slide. During analysis, the samples were rotated at 60 rpm and analyzed from angles of 4 to 40 degrees ( ⁇ -2 ⁇ ) at 5 degrees per minute with a 0.04 degree step or at 2 degrees per minute with a 0.02 degree step.
  • DSC differential scanning calorimetry
  • the DSC Densilic Acid Meltaline thermographs were obtained using a TA instrument DSC Q1000 and Mettler Toledo DSC821e instrument at a scan rate of 5 °C/min over a temperature range of 25-250°C.
  • the endotherms exhibited by the compounds of the invention may vary by about 0.01-5 °C for crystal polymorph melting above or below the endotherms depicted in the appended figures.
  • Factors responsible for such variance include the rate of heating (i.e., the scan rate) at which the DSC analysis is conducted, the way the DSC onset temperature is defined and determined, the calibration standard used, instrument calibration, the relative humidity and the chemical purity of the sample.
  • the observed endotherms may also differ from instrument to instrument; however, it will generally be within the ranges defined herein provided the instruments are calibrated similarly.
  • Raman scattering spectra were obtained by using a Dispersive Raman Spectrometer from Kaiser Optical Instruments, Raman RXN1.
  • the excitation light source was a 785-nm external-cavity-stabilized diode laser.
  • the detector was a charge-coupled device (CCD). The resolution was 4 cm -1 .
  • the infrared spectra were recorded on a Bruker Vector33 FT-IR spectrophotometer. Sample of drug substance was ground with potassium bromide and pressed into a pellet. The pellet was scanned from 4000 cm -1 to 400 cm -1 . Major peaks were marked between 3400 -1 to 500 cm -1 .
  • Different polymorphic forms of Compound I may also be distinguished by different stabilities and different solubilities.
  • the polymorphic forms of the present invention are substantially pure, meaning each polymorphic form of Compound I includes less than 10%, for example less than 5%, or for example less than 3%, or even further, for example, less than 1% by weight of impurities, including other polymorphic forms of Compound I.
  • the solid forms of the present invention may also comprise more than one polymorphic form.
  • crystalline forms of a given compound can exist in substantially pure forms of a single polymorph, and can also exist in a crystalline form that comprises two or more different polymorphs.
  • the X-ray diffraction pattern will have peaks characteristic of each of the individual polymorphs of the present invention.
  • a solid form that comprises two polymorphs will have a X-ray powder diffraction pattern that is a convolution of the two X-ray diffraction patterns that correspond to the substantially pure polymorphic forms.
  • a solid form of the present invention containing a first and second polymorphic form contains at least 10% of the first polymorph. In a further embodiment, the solid form contains at least 20% of the first polymorph. Even further embodiments contain at least 30%, at least 40%, or at least 50% of the first polymorph.
  • One of skill in the art will recognize that many such combinations of several individual polymorphs in varying amounts are possible.
  • Polymorphic Form IV of Compound I can be prepared by phosphorylation of the compound 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one represented by formula 1 in methanol.
  • Polymorphic Form IV of Compound I is physically and chemically stable at 40°C under 75% relative humidity for at least 3 months.
  • Polymorphic Form IV of Compound I has an aqueous solubility of 4.5 mg/mL at pH 5.4.
  • the DSC thermogram for Form IV shown in Figure 12 , indicates an endotherm onset at 204.0°C at a scan rate of 5°C/minute.
  • Polymorphic Form I of Compound I is a hydrate.
  • Polymorphic Form I of Compound I can be produced by treating polymorphic Form IV (MEOH solvate) with water.
  • Polymorphic Form I of Compound I is chemically stable at 40°C under 75% relative humidity for at least 3 months, but it will be converted to Form III (Hydrate B) after one week at this condition.
  • Form I is physically stable at ambient condition for at least 3 months.
  • Polymorphic Form I of Compound I has an aqueous solubility of 2.8 mg/mL at pH 5.4.
  • the DSC thermogram for Form I shown in Figure 3 , indicates an endotherm onset at 202°C at a scan rate of 5°C/minute.
  • Polymorphic Form II of Compound I is an anhydrous form. Form II can be produced by dehydration of Form I.
  • Polymorphic Form II of Compound I is physically stable at ambient condition for at least 3 months.
  • Form II can be converted to Form III (Hydrate B) at 40°C under 75% relative humidity after 1 week or at 25°C under 90% relative humidity overnight.
  • Polymorphic Form II of Compound I has an aqueous solubility of 3.0 mg/mL at pH 5.4.
  • the pH solubility study of Form II was conducted at pH range 3.0 to 8.0.
  • the buffer systems used in this study are 50 mM ammonium phosphate for pH 3.0 and 4.0, and 50 mM sodium phosphate buffer for pH 5.0 to 8.0.
  • the solubility results are shown in Table 1 and Figure 15 . It could be seen that the solubility of Form II decreases with the increase of pH from 3.0 to 8.0. Because Form II is a phosphate salt and phosphate buffers were used in the pH solubility study, the solubility determined in these buffer systems are lower than the solubility in water due to the common ion effect. Table 1. pH Solubility Profile of Form II Buffer pH Solubility (mg/mL) 3 0.46 4 0.39 5 0.37 6 0.32 7 0.25 8 0.19
  • the DSC thermogram for Form II shown in Figure 6 , indicates an endotherm onset at 205°C at a scan rate of 5°C/ minute.
  • Polymorphic Form III of Compound I is a hydrate.
  • Polymorphic Form III of Compound I can be produced by hydration of Form I or Form II.
  • Polymorphic Form III of Compound I is physically and chemically stable at 40°C under 75% relative humidity for at least 3 months.
  • Polymorphic Form III of Compound I has an aqueous solubility of 2.7 mg/mL at pH 5.4.
  • the DSC thermogram for Form III shown in Figure 9 , indicates an endotherm onset at 203°C at a scan rate of 5°C/minute.
  • Polymorphic Form V of Compound I was formed during the stability studies of Form II when stored at 40°C under 75% relative humidity for 6 months period. Polymorphic Form V of Compound I is physically and chemically stable at room temperature for at least 3 months.
  • Polymorphic Form V of Compound I has an aqueous solubility of 3.0 mg/mL at pH 5.4.
  • the DSC thermogram for Form V shown in Figure 17 , has an endotherm at 199.40°C, with two desolvation peaks at 57.29°C and 110.73°C, respectively.
  • Polymorphic Form VI of Compound I can be prepared by taking an aqueous slurry of Form II and heating at 100°C overnight As shown in Figure 14 , conversion began at 80°C and was complete following the overnight hold at 100°C.
  • the DSC thermogram for Form VI shown in Figure 20 , has an endotherm at 219.68°C, with two desolvation peaks at 88.42°C, 112°C respectively.
  • the amorphous form can be prepared by lyophilization of aqueous solution of Compound I.
  • the X-ray powder diffraction pattern of the amorphous form is characterized by a typical amorphous broad hump-peak from 4 to 40°, without any sharp peaks characteristic of crystalline forms.
  • Figure 21 provides an X-ray powder diffraction pattern for the amorphous form.
  • the infrared absorption spectrum of amorphous form, shown in Figure 22 was measured as described herein, with bands found at the flowing approximate positions (cm -1 ): 433, 505, 518, 596, 609, 654, 674, 705, 746, 785, 856, 896, 937, 955, 1020, 1066, 1106, 1132, 1217, 1260, 1319, 1349, 1367, 1419, 1452, 1472, 1508, 1579, 2300, 2349, 2407, 2830, 3031, 3256.
  • the Raman spectral diagram for the amorphous form shown in Figure 23 , includes Raman Shift peaks (cm -1 ) at approximately 1068, 1323, 1350, 1371, 1453, 1556, 1581, 1616.
  • the DSC thermogram for the amorphous form, shown in Figure 24 is notable for a lack of isolated peaks.
  • the active agents i.e., the polymorphs, or solid forms comprising two or more such polymorphs or amorphous form, of Compound I described herein
  • the active agents may be formulated into pharmaceutical compositions suitable for mammalian medical use. Any suitable route of administration may be employed for providing a patient with an effective dosage of any of polymorphic Forms I, II, III, V, and VI.
  • peroral or parenteral formulations and the like may be employed.
  • Dosage forms include capsules, tablets, dispersions, suspensions and the like, e.g. enteric-coated capsules and/or tablets, capsules and/or tablets containing enteric-coated pellets of Compound I.
  • compositions of the invention comprise a therapeutically effective amount of the active agent and one or more inert, pharmaceutically acceptable carriers, and optionally any other therapeutic ingredients, stabilizers, or the like.
  • the carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof.
  • compositions may further include diluents, buffers, binders, disintegrants, thickeners, lubricants, preservatives (including antioxidants), flavoring agents, taste-masking agents, inorganic salts (e.g., sodium chloride), antimicrobial agents (e.g., benzalkonium chloride), sweeteners, antistatic agents, surfactants (e.g., polysorbates such as "TWEEN 20" and “TWEEN 80", and pluronics such as F68 and F88, available from BASF), sorbitan esters, lipids (e.g., phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines, fatty acids and fatty esters, steroids (e.g., cholesterol)), and chelating agents (e.g., EDTA, zinc and other such suitable cations).
  • diluents e.g., buffers, binders, disintegrants, thicken
  • compositions according to the invention are listed in “ Remington: The Science & Practice of Pharmacy", 19th ed., Williams & Williams, (1995 ), and in the “ Physician's Desk Reference”, 52nd ed., Medical Economics, Montvale, NJ (1998 ), and in “ Handbook of Pharmaceutical Excipients", Third Ed., Ed. A.H. Kibbe, Pharmaceutical Press, 2000 .
  • the active agents of the invention may be formulated in compositions including those suitable for oral, rectal, topical, nasal, ophthalmic, or parenteral (including intraperitoneal, intravenous, subcutaneous, or intramuscular injection) administration.
  • compositions will generally contain anywhere from about 0.001 % by weight to about 99% by weight active agent, preferably from about 0.01% to about 5% by weight active agent, and more preferably from about 0.01% to 2% by weight active agent, and will also depend upon the relative amounts of excipients/additives contained in the composition.
  • a pharmaceutical composition of the invention is administered in conventional dosage form prepared by combining a therapeutically effective amount of an active agent as an active ingredient with one or more appropriate pharmaceutical carriers according to conventional procedures. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • the pharmaceutical carrier(s) employed may be either solid or liquid.
  • Exemplary solid carriers include sugars (for example, lactose, sucrose, mannitol, or sorbitol), talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • Exemplary liquid carriers include syrup, peanut oil, olive oil, water and the like.
  • the carrier(s) may include time-delay or time-release materials known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate and the like.
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
  • the amount of solid carrier may vary, but generally will be from about 25 mg to about 1 g.
  • the preparation can be in the form of syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in an ampoule or vial or non-aqueous liquid suspension.
  • Compound I can be dissolved in an aqueous solution of an organic or inorganic acid, such as 0.3 M solution of succinic acid or citric acid. If a soluble salt form is not available, the active agent may be dissolved in a suitable co-solvent or combinations of co-solvents. Examples of suitable co-solvents include, but are not limited to, alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, gylcerin and the like In concentrations ranging from 0-60% of the total volume.
  • the composition may also be in the form of a solution of Compound I in an appropriate aqueous vehicle such as water or Isotonic saline or dextrose solution.
  • an exemplary daily dose generally employed is from about 0.001 to about 1000 mg/kg of body weight, more preferably from about 0.001 to about 50 mg/kg body weight, with courses of treatment repeated at appropriate intervals.
  • Administration of prodrugs is typically dosed at weight levels that are chemically equivalent to the weight levels of the fully active form.
  • a suitable oral dosage form may cover a dose range from 5 mg to 250 mg total daily dose, administered in one single dose or equally divided doses.
  • a preferred dosage range is from 10 mg to 80 mg.
  • a suitable parenteral dosage form may cover a dose range from 5 mg to 200 mg total daily dose, administered in one single dose or equally divided doses.
  • a preferred dosage range is from 10 mg to 100 mg.
  • compositions of the invention may be manufactured in manners generally known for preparing pharmaceutical compositions, e.g., using conventional techniques such as mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing.
  • Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers, which may be selected from excipients and auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically.
  • the compounds can be formulated readily by combining the active agents with pharmaceutically acceptable carriers known in the art.
  • Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • Pharmaceutical preparations for oral use can be obtained using a solid excipient in admixture with the active agent, optionally grinding the resulting mixture, and processing the mixture of granules after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients include: fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; and cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • disintegrating agents may be added, such as crosslinked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, polyvinyl pyrrolidone, Carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active agents.
  • compositions that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate, and, optionally, stabilizers.
  • the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
  • the compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds for use according to the present invention can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide
  • the active agents may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit-dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions for parenteral administration include suspensions of the active agents and may be prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension may also contain suitable stabilizers or agents that increase the solubility of the active agents to allow for the preparation of highly concentrated solutions.
  • the active agent is delivered in a pharmaceutically acceptable ophthalmic vehicle such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, including, for example, the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/cilary, lens, choroid/retina and selera.
  • the pharmaceutically acceptable ophthalmic vehicle may be, for example, an ointment, vegetable oil, or an encapsulating material.
  • An active agent of the invention may also be injected directly into the vitreous and aqueous humor or subtenon.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • the compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the polymorphic forms may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
  • the polymorphic forms may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion-exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the active agents may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
  • sustained-release materials have been established and are known by those skilled in the art.
  • Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days.
  • additional strategies for protein stabilization may be employed.
  • compositions also may comprise suitable solid- or gel-phase carriers or excipients.
  • suitable solid- or gel-phase carriers or excipients include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • inventive polymorphic forms of Compound I are useful for mediating the activity of poly(ADP-ribose) polymerase (PARP). More particularly, the polymorphic forms are useful as chemosensitizers that enhances the efficacy of radiotherapy or cytotoxic drugs whose mechanism depends on DNA damage.
  • PARP poly(ADP-ribose) polymerase
  • These drugs include but not limited to temozolomide (SCHERING), irinotecan (PFIZER), topotecan (GLAXO SMITHKLINE), cisplatin (BRISTOL MEYERS SQUIBB; AM PHARM PARTNERS; BEDFORD; GENSIA SICOR PHARMS; PHARMACHEMIE), and doxorubicin hydrochloride (AM PHARM PARTNERS; BEDFORD; GENSIA; SICOR PHARMS; PHARMACHEMIE; ADRIA; ALZA).
  • SCHERING temozolomide
  • PFIZER irinotecan
  • GLAXO SMITHKLINE GLAXO SMITHKLINE
  • BRISTOL MEYERS SQUIBB AM PHARM PARTNERS
  • BEDFORD GENSIA SICOR PHARMS
  • PHARMACHEMIE doxorubicin hydrochloride
  • ADRIA ALZA
  • inventive polymorphic forms of Compound I are also useful for enhancing the induction of the expression of Reg gene in ⁇ cells and HGF gene and, accordingly, promoting the proliferation of pancreatic ⁇ -cells of Langerhans' islets and suppressing apoptosis of the cells. Further, the inventive polymorphic forms of Compound I are useful for preparing cosmetics, for example, in after-sun lotions.
  • Therapeutically effective amounts of the agents of the invention may be administered, typically in the form of a pharmaceutical composition, to treat diseases mediated by modulation or regulation of PARP.
  • An "effective amount" is intended to mean that amount of an agent that, when administered to a mammal, including a human, in need of such treatment, is sufficient to effect treatment for a disease mediated by the activity of one or more PARP enzyme.
  • a therapeutically effective amount of a compound of the invention is a quantity sufficient to modulate, regulate, or inhibit the activity of one or more PARP enzyme such that a disease condition that is mediated by that activity is reduced or alleviated.
  • Treating is intended to mean at least the mitigation of a disease condition in a mammal, including a human, that is affected, at least in part, by the activity of one or more PARP enzymes and includes: preventing the disease condition from occurring in a mammal, particularly when the mammal is found to be predisposed to having the disease condition but has not yet been diagnosed as having it; modulating and/or inhibiting the disease condition; and/or alleviating the disease condition.
  • Exemplary disease condition includes cancer.
  • the activity of the polymorphic forms of Compound I as modulators of PARP activity may be measured by any of the methods available to those skilled in the art, including in vivo and/or in vitro assays. Examples of suitable assays for activity measurements include those described in U.S. Patent No. 6,495,541 and U.S. Provisional Patent Application No. 60/612,458 .
  • the present invention is also directed to the compounds in accordance with the invention for use in treating a disease condition mediated by PARP activity, for example, cancer and a variety of disease and toxic states that involve oxidative or nitric oxide induced stress and subsequent PARP hyperactivation.
  • a disease condition mediated by PARP activity for example, cancer and a variety of disease and toxic states that involve oxidative or nitric oxide induced stress and subsequent PARP hyperactivation.
  • diseases include, but not limited to, neurologic and neurodegenerative disorders (eg, Parkinson's disease, Alzheimer's disease), cardiovascular disorders (e.g., myocardial infarction, ischemia-reperfusion injury), diabetic vascular dysfunction, cisplatin-induced nephrotoxicity.
  • the therapeutic methods of the present invention comprise administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition which comprises any of the polymorphic forms, or pharmaceutical compositions discussed above.
  • the compounds of the present invention can also be used in combination therapeutic methods of treating a disease condition mediated by PARP activity, which comprises administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition which comprises any of the polymorphic forms, or pharmaceutical compositions discussed above, in combination with a therapeutically effective amount of one or more substances selected from anti-tumor agents, anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents.
  • substances include those disclosed in PCT Publication Nos.
  • WO 00/38715 WO 00/38716 , WO 00/38717 , WO 00/38718 , WO 00/38719 , WO 00/38730 , WO 00/38665 , WO 00/37107 and WO W0/38786 .
  • anti-tumor agents examples include temozolomide (SCHERING), irinotecan (PFIZER), topotecan (GLAXO SMITHKLINE), cisplatin (BRISTOL MEYERS SQUIBB; AM PHARM PARTNERS; BEDFORD; GENSIA SICOR PHARMS; PHARMACHEMIE), and doxorubicin hydrochloride (AM PHARM PARTNERS; BEDFORD; GENSIA; SICOR PHARMS; PHARMACHEMIE; ADRIA; ALZA).
  • SCHERING temozolomide
  • PFIZER irinotecan
  • GLAXO SMITHKLINE GLAXO SMITHKLINE
  • BRISTOL MEYERS SQUIBB AM PHARM PARTNERS
  • BEDFORD GENSIA SICOR PHARMS
  • PHARMACHEMIE doxorubicin hydrochloride
  • ADRIA ALZA
  • anti-tumor agents include mitotic inhibitors, for example vinca alkaloid derivatives such as vinblastine vinorelbine, vindescine and vincristine; colchines allochochine, halichondrine, N-benzoyltrimethyl-methyl ether colchicinic acid, dolastatin 10, maystansine, rhizoxine, taxanes such as taxol (paclitaxel), docetaxel (Taxotere), 2'-N-[3-(dimethylamino)propyl]glutaramate (taxol derivative), thiocholchicine, trityl cysteine, teniposide, methotrexate, azathioprine, fluorouricil, cytocine arabinoside, 2'2'-difluorodeoxycytidine (gemcitabine), adriamycin and mitamycin.
  • mitotic inhibitors for example vinca alkaloid derivatives such as vinblastine vinorelbine
  • Alkylating agents for example, carboplatin, oxiplatin, iproplatin, ethyl ester of N-acetyl-DL-sarcosyl-L-feucine (Asaley or Asalex), 1,4-cyclohexadiene-1,4-dicarbamic acid, 2,5-bis(1-azirdinyl)-3,6-dioxo-, diethyl ester (diaziquone), 1,4-bis(methanesulfonyloxy)butane (bisulfan or leucosulfan), chlorozotocin, clomesone, cyanomorpholinodoxorubicin, cyclodisone, dianhydroglactitol, fluorodopan, hepsulfam, mitomycin C, hycantheonemitomycin C, mitozolamide, 1-(2-chloroethyl)-4-(3-chloropropyl)-piperazine di
  • DNA anti-metabolites for example 5-fluorouracil, cytosine arabinoside, hydroxyurea, 2-[(3hydroxy-2-pyrinodinyl)methylene]-hydrazinecarbothioamide, deoxyfluorouridine, 5-hydroxy-2-formylpyridine thiosemicarbazone, alpha-2'-deoxy-6-thioguanosine, aphidicolin glycinate, 5-azadeoxycytidine, beta-thioguanine deoxyriboside, cyclocytidine, guanazole, inosine glycodialdehyde, macbecin II, pyrazolimidazole, cladribine, pentostatin, thioguanine, mercaptopurine, bleomycin, 2-chlorodeoxyadenosine, inhibitors of thymidylate synthase such as raltitrexed and pemetrexed disodium, clofarabine, floxuridine
  • DNA/RNA antimetabolites for example, L-alanosine, 5-azacytidine, acivicin, aminopterin and derivatives thereof such as N-[2-chloro-5-[[(2, 4-diamino-5-methyl-6-quinazolinyl)methyl]amino]benzoyl]-L-aspartic acid, N-[4-[[(2, 4-diamino-5-ethyl-6-quinazolinyl)methyl]amino]benzoyl]-L-aspartic acid, N -[2-chloro-4-[[(2, 4-diaminopteridinyl)methyl]amino]benzoyl]L-aspartic acid, soluble Baker's antifol, dichloroallyl lawsone, brequinar, ftoraf, dihydro-5-azacytidine, methotrexate, N-(phosphonoacetyl)-L-aspartie acid te
  • Anti-angiogenesis agents include MMP-2 (matrix-metalloprotienase 2) inhibitors, MMP-9 (matrix-metalloprotienase 9) inhibitors, and COX-II (cyclooxygenase II) inhibitors.
  • MMP-2 matrix-metalloprotienase 2
  • MMP-9 matrix-metalloprotienase 9
  • COX-II cyclooxygenase II
  • useful COX-II inhibitors include CELEBREX TM (alecoxib), valdecoxib, and rofecoxib.
  • Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published October 24, 1996 ), WO 96/27583 (published March 7, 1996 ), European Patent Application No. 97304971.1 (filed July 8, 1997 ), European Patent Application No.
  • MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP-2 and/or MMP-9 relative to the other matrix-metalloproteinases (i.e. MMP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13).
  • MMP inhibitors include AG-3340, RO 32-3555, RS 13-0830, and the following compounds: 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-cyclopentyl)-amino]-propionic acid; 3-exo-3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1]octane-3-carboxylic acid hydroxyamide; (2R, 3R) 1-[4-(2-chloro-4-fluoro-benzyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl-piperidine-2-carboxylic acid hydroxyamide; 4-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-4-carboxylic acid hydroxyamide; 3-[[4-(4-
  • signal transduction inhibitors include agents that can inhibit EGFR (epidermal growth factor receptor) responses, such as EGFR antibodies, EGF antibodies, and molecules that are EGFR inhibitors; VEGF (vascular endothelial growth factor) inhibitors; and erbB2 receptor inhibitors, such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTIN TM (Genentech, Inc. of South San Francisco, California, USA).
  • EGFR epidermal growth factor receptor
  • VEGF vascular endothelial growth factor
  • erbB2 receptor inhibitors such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTIN TM (Genentech, Inc. of South San Francisco, California, USA).
  • EGFR inhibitors are described in, for example in WO 95/19970 (published July 27, 1995 ), WO 98/14451 (published April 9, 1998 ), WO 98/02434 (published January 22, 1998 ), and United States Patent 5,747,498 (issued May 5, 1998 ).
  • EGFR-inhibiting agents include, but are not limited to, the monoclonal antibodies C225 and anti-EGFR 22Mab (ImClone Systems Incorporated of New York, New York, USA), the compounds ZD-1839 (AstraZeneca), BIBX-1382 (Boehringer Ingelheim), MDX-447 (Medarex Inc. of Annandale, New Jersey, USA), and OL-X-103 (Merck & Co. of Whitehouse Station, New Jersey, USA), VRCTC-310 (Ventech Research) and EGF fusion toxin (Seragen Inc. of Hopkinton, Massachusetts).
  • VEGF inhibitors for example SU-5416 and SU-6668 (Sugen Inc. of South San Francisco, California, USA), can also be combined or co-administered with the composition.
  • VEGF inhibitors are described in, for example in WO 99/24440 (published May 20, 1999 ), PCT International Application PCT/IB99/00797 (filed May 3, 1999 ), in WO 95/21613 (published August 17, 1995 ), WO 99/61422 (published December 2, 1999 ), United States Patent 5,834,504 (issued November 10, 1998 ), WO 98/50356 (published November 12, 1998 ), United States Patent 5,883,113 (issued March 16, 1999 ), United States Patent 5,886,020 (issued March 23, 1999 ), United States Patent 5,792,783 (issued August 11, 1998 ), WO 99/10349 (published March 4, 1999 ), WO 97/32856 (published September 12, 1997 ), WO 97/22596 (published June 26, 1997 ), WO 98/54093 (published December 3, 1998
  • VEGF inhibitors include IM862 (Cytran Inc. of Kirkland, Washington, USA); anti-VEGF monoclonal antibody bevacizumab (Genentech, Inc. of South San Francisco, California); and angiozyme, a synthetic ribozyme from Ribozyme (Boulder, Colorado) and Chiron (Emeryville, California).
  • ErbB2 receptor inhibitors such as GW-282974 (Glaxo Wellcome plc), and the monoclonal antibodies AR-209 (Aronex Pharmaceuticals Inc. of The Woodlands, Texas, USA) and 2B-1 (Chiron), may be administered in combination with the composition.
  • Such erbB2 inhibitors include those described in WO 98/02434 (published January 22, 1998 ), WO 99/35146 (published July 15, 1999 ), WO 99/35132 (published July 15, 1999 ), WO 98/02437 (published January 22, 1998 ); WO 97/13760 (published April 17, 1997 ), WO 95/19970 (published July 27, 1995 ), United States Patent 5,587,458 (issued December 24, 1996 ), and United States Patent 5,877,305 (issued March 2, 1999 ).
  • ErbB2 receptor inhibitors useful in the present invention are also described in United States Provisional Application No. 60/117,341, filed January 27, 1999 , and in United States Provisional Application No. 60/117,346, filed January 27, 1999 .
  • antiproliferative agents include inhibitors of the enzyme farnesyl protein transferase and inhibitors of the receptor tyrosine kinase PDGFr, including the compounds disclosed and claimed in the following United States patent applications: 09/221946 (filed December 28, 1998 ); 09/454058 (filed December 2, 1999 ); 09/501163 (filed February 9, 2000 ); 09/539930 (filed March 31, 2000 ); 09/202796 (filed May 22, 1997 ); 09/384339 (filed August 26, 1999 ); and 09/383755 (filed August 26, 1999 ); and the compounds disclosed and claimed in the following United States provisional patent applications: 60/168207 (filed November 30, 1999 ); 60/170119 (filed December 10, 1999 ); 60/177718 (filed January 21, 2000 ); 60/168217 (filed November 30, 1999 ), and 60/200834 (filed May 1, 2000 ).
  • compositions of the invention can also be used with other agents useful in treating abnormal cell growth or cancer, including, but not limited to, agents capable of enhancing antitumor immune responses, such as CTLA4 (cytotoxic lymphocite antigen 4) antibodies, and other agents capable of blocking CTLA4; and anti-proliferative agents such as other farnesyl protein transferase inhibitors.
  • agents capable of enhancing antitumor immune responses such as CTLA4 (cytotoxic lymphocite antigen 4) antibodies, and other agents capable of blocking CTLA4; and anti-proliferative agents such as other farnesyl protein transferase inhibitors.
  • CTLA4 cytotoxic lymphocite antigen 4
  • anti-proliferative agents such as other farnesyl protein transferase inhibitors.
  • Polymorphic Form IV of Compound I was prepared by the following procedure. A 500 mL round bottom flask was charged with the compound 8-fluoro-2- ⁇ 4-[(methylamino)methyl]phenyl ⁇ -1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one represented by formula 1 (1.65 g, 5.10 mmol, 1.0 equiv.) and methanol (200 mL). The mixture was agitated until clear solution was obtained (-10 minutes).
  • Figure 10 is an X-ray powder diffractogram of polymorphic Form IV of Compound I.
  • Figure 11 is an infrared absorption spectrum of polymorphic Form IV.
  • Polymorphic Form IV of Compound I was further characterized by differential scanning calorimetry ( Figure 12 ).
  • Polymorphic Form I of Compound I was produced by the following procedure. A 50 mL round bottom flask was charged with polymorphic Form IV (methanol solvate) of Compound I (1.0 g) slurried with 10 mL of water and stirred for at 18-24 hrs at ambient temperature. The solids obtained were filtered, dried at 45°C to afford polymorphic Form I of Compound I (0.67 g). The product was analyzed for absence of methanol by NMR.
  • polymorphic Form IV methanol solvate
  • Figure 1 is an X-ray powder diffractogram of polymorphic Form I of Compound I.
  • Figure 2 is an infrared absorption spectrum of polymorphic Form I.
  • Polymorphic Form I of Compound I was further characterized by differential scanning calorimetry ( Figure 3 ).
  • Figure 4 is an X-ray powder diffractogram of polymorphic Form II of Compound I.
  • Figure 5 is an infrared absorption spectrum of polymorphic Form II.
  • Polymorphic Form II of Compound I was further characterized by differential scanning calorimetry ( Figure 6 ).
  • Form II is stored at 2-8°C with desiccant.
  • Figure 7 is an X-ray powder diffractogram of polymorphic Form III of Compound I.
  • Figure 8 is an infrared absorption spectrum of polymorphic Form III.
  • Polymorphic Form III of Compound I was further characterized by differential scanning calorimetry ( Figure 9 ).
  • Polymorphic Form V of Compound I was formed during the stability studies of Form II when stored at 40°C under 75% relative humidity for 6 months period. Polymorphic Form V of Compound I is physically and chemically stable at room temperature for at least 3 months.
  • Polymorphic Form V of Compound I has an aqueous solubility of 3.0 mg/mL at pH 5.4.
  • Figure 13 provides an X-ray powder diffraction pattern of Form V.
  • Figure 16 is an infrared absorption spectrum of polymorphic Form V of Compound I.
  • the DSC thermogram for Form V has an endotherm at 199.40°C, with two desolvation peaks at 57.29°C and 110.73°C, respectively ( Figure 17 ).
  • Polymorphic Form VI of Compound I can be prepared by taking an aqueous slurry of Form II and heating at 100°C overnight As shown in Figure 14 , conversion began at 80°C and was complete following the overnight hold at 100°C.
  • Polymorphic Form VI has the characteristics described above.
  • Figure 18 is an X-ray powder diffraction diagram of polymorphic Form VI of Compound I.
  • Figure 19 is an infrared absorption spectrum of polymorphic Form VI of Compound I.
  • Figure 20 is a differential scanning calorimetry (DSC) profile of polymorphic Form VI of Compound I.
  • Polymorphic Form II (Anhydrous Form) of Compound I was used for preparation of a lyophilized powder for injection, 12 mg/vial (as free base), intended for clinical use, are provided below.
  • the drug product is first formulated as a Compound I solution for lyophilization.
  • the quantitative composition of the Compound I solution for lyophilization is presented in Table 2.
  • Table 2. Compound I Solution for Lyophilization, 3 mg/mL (as free base) Names of Ingredients Theoretical Quantity (mg/mL) Percentage Formula (% w/w) Function Compound I 3.9 (Equivalent to 3.0 of its free base) 0.4 Active ingredient Mannitol 50.0 4.9 Bulking agent Water for Injection 963.1 94.7 Solvent Total 1017.0 100.0 -
  • the clinical composition of Compound I Lyophilized Powder for Injection 12 mg/vial (as free base), contains a theoretical overage of 0.45 mg/vial (as free base). This overage compensates for the solid volume in the vial upon reconstitution with 6 mL of Sterile Water for Injection (SWFI) and ensures the delivery of a 2.02 mg/mL (as free base) drug solution.
  • SWFI Sterile Water for Injection
  • the components of the packaging system for Compound I Lyophilized Powder for Injection, 12 mg/vial (as free base), are listed below: Component Description Vial 10 mL/20 mm, Type I amber glass vial Stopper 20 mm 4432/50 (uncoated chlorobutyl) B2-40 stopper, 1319 design Seal 20 mm aluminum overcap
  • Lyophilized Powder for Injection is a conventional dosage form for administration.
  • the clinical formulation contains mannitol as a bulking agent and a tonicity adjuster. Reconstitution of the drug product with 6 mL SWFI yields a clear, hypotonic, 2.02 mg/mL (as free base) solution. The reconstituted drug product will be diluted with an acceptable Isotonic sterile diluent for infusion.
  • the clinical drug product was originally designed for reconstitution with 4 mL SWFI to yield a clear, isotonic, 3 mg/mL (as free base) solution.
  • SWFI a drug substance polymorph
  • the aqueous solubility of polymorphic Form III (Hydrate B) is 2.7 mg/mL at pH 5.4 and is thus very close to the original target drug product reconstitution concentration (3 mg/mL).
  • the SWFI reconstitution volume was changed from 4 mL to 6 mL to ensure complete drug dissolution.
  • the resulting final concentration of the constituted drug product solution is 2.02 mg/mL (as free base), well below the aqueous solubility of polymorphic Form III (Hydrate B).
  • the manufacturing process for Compound I Lyophilized Powder for Injection, 12 mg/vial (as free base) is summarized below.
  • the current clinical batch size is 9.3 L per manufacturing campaign.
  • the manufacturing formula is the same as the clinical composition (see Table 2 and Table 3).
  • the amorphous form of Compound I was prepared by dissolving polymorphic Form II (anhydrous form) of Compound I in sterile water for injection at concentration of 4.46 mg/mL. 2 mL of this solution was filled in 10 mL clear Type I vial and lyophilized in FTS LyoStar Lyophilizer (S/N LSACC3). The lyophilization cycle is described as follows.
  • the product was frozen to -50 °C and subsequently vacuum dried at -30 °C, -20 °C and -15 °C for 12 hr each to complete the primary drying step.
  • the vacuum pressure was kept at 200 mtorr.
  • the product was further dried at 25 °C and at vacuum 200 mtorr for 24 hr to complete the secondary drying step.
  • the amorphous form of Compound I was obtained as the white/yellowish lyophilized cake.
  • the amorphous form of Compound I can be reconstituted with 2 mL sterile water for injection to yield a clear yellow solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05799991A 2004-09-22 2005-09-12 Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one Active EP1799685B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61245904P 2004-09-22 2004-09-22
US67929605P 2005-05-09 2005-05-09
PCT/IB2005/002941 WO2006033007A2 (en) 2004-09-22 2005-09-12 Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Publications (2)

Publication Number Publication Date
EP1799685A2 EP1799685A2 (en) 2007-06-27
EP1799685B1 true EP1799685B1 (en) 2012-03-28

Family

ID=35526956

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05799991A Active EP1799685B1 (en) 2004-09-22 2005-09-12 Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Country Status (18)

Country Link
US (1) US7268126B2 (pt)
EP (1) EP1799685B1 (pt)
JP (1) JP2008513436A (pt)
KR (1) KR100853601B1 (pt)
AR (1) AR051296A1 (pt)
AT (1) ATE551345T1 (pt)
AU (1) AU2005286191B2 (pt)
BR (1) BRPI0516766A (pt)
CA (1) CA2581025C (pt)
ES (1) ES2382950T3 (pt)
HK (1) HK1116483A1 (pt)
IL (1) IL181463A (pt)
MX (1) MX2007002461A (pt)
NO (1) NO337938B1 (pt)
NZ (1) NZ554659A (pt)
RU (1) RU2355691C2 (pt)
TW (1) TWI365188B (pt)
WO (1) WO2006033007A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087713A1 (en) * 2003-03-31 2004-10-14 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
NZ587586A (en) * 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US8143447B2 (en) * 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
CN101534836B (zh) * 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
WO2008114114A2 (en) * 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
NZ586125A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2009064444A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
CN101888777A (zh) * 2007-12-07 2010-11-17 彼帕科学公司 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
EP2250282A4 (en) * 2008-02-04 2011-05-18 Bipar Sciences Inc METHOD FOR THE DIAGNOSIS AND TREATMENT OF PARP-MEDIATED DISEASES
RU2567792C2 (ru) 2009-11-09 2015-11-10 Аллерган, Инк. Композиции и способы стимулирования роста волос
DK3150610T3 (da) 2010-02-12 2019-11-04 Pfizer Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
CA2798697A1 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
RU2641021C2 (ru) 2013-02-15 2018-01-17 Аллерган, Инк. Имплантат для пролонгированной доставки лекарственного средства
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
KR20170043597A (ko) 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
DK3594343T3 (da) 2015-07-23 2021-06-28 Inst Curie Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
KR20190110579A (ko) 2017-01-24 2019-09-30 아시아 케미컬 인더스트리스 리미티드 루카파립 및 루카파립 염의 고체상 형태
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN110997068B (zh) * 2017-05-24 2022-12-06 宾夕法尼亚大学董事会 用于成像和放射疗法的经放射标记的荧光parp抑制剂
MX2020004545A (es) 2017-11-03 2020-08-03 Sandoz Ag Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa.
CR20200334A (es) 2018-01-05 2021-03-09 Cybrexa 1 Inc Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
JP2022541747A (ja) 2019-07-10 2022-09-27 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4100125A1 (en) 2020-02-03 2022-12-14 Sandoz AG Polymorph of rucaparib mesylate
CA3176206A1 (en) 2020-04-28 2021-11-04 Debnath Bhuniya Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022015557A1 (en) 2020-07-14 2022-01-20 Assia Chemical Industries Ltd Solid state forms of rucaparib salts
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
AU2022255809A1 (en) 2021-04-08 2023-10-26 Incozen Therapeutics Pvt. Ltd. Inhibitors of poly(adp-ribose) polymerase
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302941B6 (cs) * 1999-01-11 2012-01-25 Agouron Pharmaceuticals, Inc. Tricyklická sloucenina a farmaceutický prostredek s jejím obsahem
WO2004087713A1 (en) * 2003-03-31 2004-10-14 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
DK1660095T3 (da) * 2003-07-25 2010-05-25 Cancer Rec Tech Ltd Tricykliske PARP-inhibitorer

Also Published As

Publication number Publication date
ATE551345T1 (de) 2012-04-15
RU2355691C2 (ru) 2009-05-20
EP1799685A2 (en) 2007-06-27
IL181463A0 (en) 2007-07-04
IL181463A (en) 2012-02-29
JP2008513436A (ja) 2008-05-01
KR20070089121A (ko) 2007-08-30
ES2382950T3 (es) 2012-06-14
MX2007002461A (es) 2008-03-13
US20060100198A1 (en) 2006-05-11
BRPI0516766A (pt) 2008-09-16
KR100853601B1 (ko) 2008-08-22
CA2581025A1 (en) 2006-03-30
WO2006033007A3 (en) 2006-11-02
AR051296A1 (es) 2007-01-03
RU2007110026A (ru) 2008-10-27
NZ554659A (en) 2010-08-27
AU2005286191A1 (en) 2006-03-30
NO20070920L (no) 2007-03-15
AU2005286191B2 (en) 2011-11-17
NO337938B1 (no) 2016-07-11
TW200613305A (en) 2006-05-01
TWI365188B (en) 2012-06-01
HK1116483A1 (pt) 2008-12-24
US7268126B2 (en) 2007-09-11
WO2006033007A2 (en) 2006-03-30
CA2581025C (en) 2011-06-07

Similar Documents

Publication Publication Date Title
EP1799685B1 (en) Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US10278974B2 (en) Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070502

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080918

RTI1 Title (correction)

Free format text: POLYMORPHIC FORMS OF THE PHOSPHATE SALT OF 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-1,3,4,5-TETRAHYDRO-6H-AZEPINO(5,4,3-CD)INDOL-6-ONE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 551345

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005033427

Country of ref document: DE

Effective date: 20120524

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2382950

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120614

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20120328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120629

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 551345

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120728

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130103

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005033427

Country of ref document: DE

Effective date: 20130103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120930

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050912

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230528

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230810

Year of fee payment: 19

Ref country code: IE

Payment date: 20230725

Year of fee payment: 19

Ref country code: GB

Payment date: 20230720

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230721

Year of fee payment: 19

Ref country code: DE

Payment date: 20230726

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231009

Year of fee payment: 19